Gray platelet syndrome and defective thrombo-inflammation in Nbeal2-deficient mice

Journal of Clinical Investigation

Volumn 123, Issue 8, 2013, Pages 3331-3342

  Deppermann, Carsten ^a   Cherpokova, Deya ^a   Nurden, Paquita ^a,b   Schulz, Jan Niklas ^c   Thielmann, Ina ^a   Kraft, Peter ^d   Vögtle, Timo ^a   Kleinschnitz, Christoph ^d   Dütting, Sebastian ^a   Krohne, Georg ^a   Eming, Sabine A ^c,e   Nurden, Alan T ^b   Eckes, Beate ^c   Stoll, Guido ^d   Stegner, David ^a,d   Nieswandt, Bernhard ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b Ctr Geriatrie Ctr Hosp Univ B   (France)

^c UNIVERSITY OF COLOGNE   (Germany)

^d Department of Neurology ^*  (Germany)

^e Center for Molecular Medicine   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROBEACHIN LIKE 2; PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY THROMBOSIS; ARTICLE; BIOGENESIS; BLOOD CLOTTING; BRAIN ISCHEMIA; CELL DIFFERENTIATION; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; GRANULATION TISSUE; GRAY PLATELET SYNDROME; INFLAMMATION; MEGAKARYOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOSIS;

EID: 84881254041     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI69210     Document Type: Article

References (65)

1. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med. 2008;359(9):938-949.
2. Jackson SP. Arterial thrombosis-insidious, unpredictable and deadly. Nat Med. 2011;17(11):1423-1436.
3. Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discovery. 2003;2(1):15-28.
4. Blair P, Flaumenhaft R. Platelet α-granules: basic biology and clinical correlates. Blood Rev. 2009; 23(4):177-189.
5. Nurden A. Platelets, inflammation and tissue regeneration. Thromb Haemost. 2011;105(6):S13-S33.
6. Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev. 2003; 83(3):835-870.
7. Wilgus TA, et al. Novel function for vascular endothelial growth factor receptor-1 on epidermal keratinocytes. Am J Pathol. 2005;167(5):1257-1266.
8. Eming SA, Krieg T. Molecular mechanisms of VEGF-A action during tissue repair. J Investig Dermatol Symp Proc. 2006;11(1):79-86.
9. Seppä H, Grotendorst G, Seppa S, Schiffmann E, Martin GR. Platelet-derived growth factor is chemotactic for fibroblasts. J Cell Biol. 1982;92(2):584-588.
10. Kulkarni AB, et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A. 1993;90(2):770-774.
11. Rosa J, George J. Gray platelet syndrome. Demonstration of alpha granule membranes that can fuse with the cell surface. J Clin Invest. 1987;80(4):1138-1146.
12. Gunay-Aygun M, et al. Gray platelet syndrome: natural history of a large patient cohort and locus assignment to chromosome 3p. Blood. 2010; 116(23):4990-5001.
13. Nurden AT, Nurden P. The gray platelet syndrome: clinical spectrum of the disease. Blood Rev. 2007; 21(1):21-36.
14. Jantunen E, Hänninen A, Naukkarinen A, Vornanen M, Lahtinen R. Gray platelet syndrome with splenomegaly and signs of extramedullary hematopoiesis: a case report with review of the literature. Am J Hematol. 1994;46(3):218-224.
15. Gootenberg J, Buchanan G. Severe hemorrhage in a patient with gray platelet syndrome. J Pediatr. 1986; 109(6):1017-1019.
16. Stenberg PE, et al. Prolonged bleeding time with defective platelet filopodia formation in the Wistar Furth rat. Blood. 1998;91(5):1599-1608.
17. Wang Y, et al. Pleiotropic platelet defects in mice with disrupted FOG1-NuRD interaction. Blood. 2011; 118(23):6183-6191.
18. Kimura Y, et al. Zinc finger protein, Hzf, is required for megakaryocyte development and hemostasis. J Exp Med. 2002;195(7):941-952.
19. Albers CA, et al. Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome. Nat Genet. 2011;43(8):735-737.
20. Kahr WH, et al. Mutations in NBEAL2, encoding a BEACH protein, cause gray platelet syndrome. Nat Genet. 2011;43(8):738-740.
21. Gunay-Aygun M, et al. NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet α-granules. Nat Genet. 2011;43(8):732-734.
22. Wang X, et al. Neurobeachin: A protein kinase A-anchoring, beige/Chediak-higashi protein homolog implicated in neuronal membrane traffic. J Neurosci. 2000;20(23):8551-8565.
23. Medrihan L, et al. Neurobeachin, a protein implicated in membrane protein traffic and autism, is required for the formation and functioning of central synapses. J Physiol. 2009;587(21):5095-5106.
24. Maynard DM, Heijnen HFG, Gahl WA, Gunay- Aygun M. The α-granule proteome: novel proteins in normal and ghost granules in gray platelet syndrome. J Thromb Haemost. 2010;8(8):1786-1796.
25. Falik-Zaccai TC, et al. A new genetic isolate of gray platelet syndrome (GPS): clinical, cellular, and hematologic characteristics. Mol Genet Metab. 2001; 74(3):303-313.
26. Gebrane-Younès J, Cramer EM, Orcel L, Caen JP. Gray platelet syndrome. Dissociation between abnormal sorting in megakaryocyte alpha-granules and normal sorting in Weibel-Palade bodies of endothelial cells. J Clin Invest. 1993;92(6):3023-3028.
27. Nieswandt B, Kleinschnitz C, Stoll G. Ischaemic stroke: a thrombo-inflammatory disease? J Physiol. 2011;589(17):4115-4123.
28. Stoll G, Kleinschnitz C, Nieswandt B. Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and targets for treatment. Blood. 2008;112(9):3555-3562.
29. Kleinschnitz C, et al. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation. 2007; 115(17):2323-2330.
30. Eming SA, Hammerschmidt M, Krieg T, Roers A. Interrelation of immunity and tissue repair or regeneration. Semin Cell Dev Biol. 2009;20(5):517-527.
31. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol. 2002;3(5):349-363.
32. Raccuglia G. Gray platelet syndrome. Am J Med. 1971;51(12):818-828.
33. Bottega R, et al. Correlation between platelet phenotype and NBEAL2 genotype in patients with congenital thrombocytopenia and α-granule deficiency. Haematologica. 2013;98(6):868-874.
34. El Golli N, Issertial O, Rosa J-P, Briquet-Laugier V. Evidence for a granule targeting sequence within platelet factor 4. J Biol Chem. 2005;280(34):30329-30335.
35. Italiano JE, et al. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood. 2008;111(3):1227-1233.
36. Kamykowski J, Carlton P, Sehgal S, Storrie B. Quantitative immunofluorescence mapping reveals little functional coclustering of proteins within platelet α-granules. Blood. 2011;118(5):1370-1373.
37. Silverstein RL, Leung LL, Nachman RL. Thrombospondin: a versatile multifunctional glycoprotein. Arterioscler Thromb Vasc Biol. 1986;6(3):245-253.
38. Heilmann E, Hourdille P, Pruvost A, Paponneau A, Nurden AT. Thrombin-induced platelet aggregates have a dynamic structure. Time- dependent redistribution of glycoprotein IIb-IIIa complexes and secreted adhesive proteins. Arterioscler Thromb Vasc Biol. 1991;11(3):704-718.
39. Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost. 1990;16(1):1-20.
40. André P, et al. CD40L stabilizes arterial thrombi by a beta3 integrin - dependent mechanism. Nat Med. 2002;8(3):247-252.
41. Varga-Szabo D, et al. The calcium sensor STIM1 is an essential mediator of arterial thrombosis and ischemic brain infarction. J Exp Med. 2008; 205(7):1583-1591.
42. Heemskerk JWM, Mattheij NJA, Cosemans JMEM. Platelet-based coagulation: different populations, different functions. J Thromb Haemost. 2013;11(1):2-16.
43. Suzuki J, Umeda M, Sims PJ, Nagata S. Calciumdependent phospholipid scrambling by TMEM16F. Nature. 2010;468(7325):834-838.
44. Yang H, et al. TMEM16F Forms a Ca(2+)-activated cation channel required for lipid scrambling in platelets during blood coagulation. Cell. 2012; 151(1):111-122.
45. Sachs UJH, Nieswandt B. In vivo thrombus formation in murine models. Circ Res. 2007;100(7):979-991.
46. Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell. 1998;94(5):657-666.
47. Yang H, et al. Fibrinogen and von Willebrand factor- independent platelet aggregation in vitro and in vivo. J Thromb Haemost. 2006;4(10):2230-2237.
48. Denis C, et al. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci U S A. 1998;95(16):9524-9529.
49. Falati S, et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med. 2003;197(11):1585-1598.
50. Morowski M, Vögtle T, Kraft P, Kleinschnitz C, Stoll G, Nieswandt B. Only severe thrombocytopenia results in bleeding and defective thrombus formation in mice [published online ahead of print April 12, 2013]. Blood. doi:10.1182/blood-2012-10-461459.
51. Kleinschnitz C, et al. Deficiency of von Willebrand factor protects mice from ischemic stroke. Blood. 2009;113(15):3600-3603.
52. Goerge T, et al. Inflammation induces hemorrhage in thrombocytopenia. Blood. 2008;111(10):4958-4964.
53. Akingboye A, et al. Application of autologous derived-platelet rich plasma gel in the treatment of chronic wound ulcer: diabetic foot ulcer. J Extra Corpor Technol. 2010;42(1):20-29.
54. Everts P, et al. Is the use of autologous platelet-rich plasma gels in gynecologic, cardiac, and general reconstructive surgery beneficial? Curr Pharm Biotechnol. 2012;13(7):1163-1172.
55. Nurden A, Nurden P, Sanchez M, Andia I, Anitua E. Platelets and wound healing. Front Biosci. 2008; 13:3532-3548.
56. Szpaderska A, Egozi E, Gamelli R, DiPietro L. The effect of thrombocytopenia on dermal wound healing. J Investig Dermatol Symp Proc. 2003; 120(6):1130-1137.
57. Scherer SS, et al. Nonactivated versus thrombin-activated platelets on wound healing and fibroblast- to-myofibroblast differentiation in vivo and in vitro. Plast Reconstr Surg. 2012;129(1):46e-54e.
58. Lucas T, et al. Differential roles of macrophages in diverse phases of skin repair. J Immunol. 2010; 184(7):3964-3977.
59. Knight CG, et al. Collagen-platelet interaction: Gly- Pro-Hyp is uniquely specific for platelet Gp VI and mediates platelet activation by collagen. Cardiovasc Res. 1999;41(2):450-457.
60. Bergmeier W, et al. Rhodocytin (aggretin) activates platelets lacking alpha(2)beta(1) integrin, glycoprotein VI, and the ligand-binding domain of glycoprotein Ibalpha. J Biol Chem. 2001;276(27):25121-25126.
61. Nieswandt B, Bergmeier W, Schulte V, Rackebrandt K, Gessner JE, Zirngibl H. Expression and function of the mouse collagen receptor glycoprotein VI is strictly dependent on its association with the FcRgamma chain. J Biol Chem. 2000;275(31):23998-24002.
62. Poujol C, Ware J, Nieswandt B, Nurden AT, Nurden P. Absence of GPIbalpha is responsible for aberrant membrane development during megakaryocyte maturation: ultrastructural study using a transgenic model. Exp Hematol. 2002;30(4):352-360.
63. Nieswandt B, et al. Glycoprotein VI but not alpha- 2beta1 integrin is essential for platelet interaction with collagen. EMBO J. 2001;20(9):2120-2130.
64. Zweers MC, et al. Integrin alpha2beta1 is required for regulation of murine wound angiogenesis but is dispensable for reepithelialization. J Invest Dermatol. 2007;127(2):467-478.
65. Tomasek JJ, McRae J, Owens GK, Haaksma CJ. Regulation of alpha-smooth muscle actin expression in granulation tissue myofibroblasts is dependent on the intronic CArG element and the transforming growth factor-beta1 control element. Am J Pathol. 2005;166(5):1343-1351.